NASDAQ · ADAG
Adagene Inc.
$2.52-$0.16 (-5.97%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.04% below the high.
Loading market information…
AMEX · NSRX · USD
Stock price, earnings
Quote as of Oct 30, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nasus Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nasus Pharma Ltd.’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of -$0.73. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nasus Pharma Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.52-$0.16 (-5.97%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.04% below the high.
$6.30-$0.34 (-5.12%)
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.45% below the high.
$1.66-$0.10 (-5.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 53.37% below the high.
$1.92-$0.08 (-4.0%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.62% below the high.
$1.88-$0.06 (-3.09%)
XBiotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.35% below the high.
$1.14-$0.05 (-4.2%)
Gain Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.73% below the high.
$1.12-$0.05 (-4.27%)
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.91% below the high.
$3.40-$0.18 (-5.03%)
Adicet Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.73% below the high.
